NASDAQ:EARS
Delisted

Auris Medical Holding AG Stock Company Profile

$0.750
-0.0010 (-0.133%)
At Close: May 27, 2022

Information

Bahnhofstrasse 21

Zug 6300

41 41 729 71 94

www.aurismedical.com

Auris Medical Holding AG

Description

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical development for treating acute inner ear tinnitus. The company is also developing AM-111 for the treatment of acute sensorineural hearing loss; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, and drug delivery devices and formulations for the treatment of inner ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is based in Zug, Switzerland.

Click to get the best stock tips daily for free!

About Auris Medical Holding AG

Auris Medical Holding AG Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical development for treating acute inner ear tinnitus. The company is also developing AM-111 for the treatment of acute sensorineural hearing loss; and other pre-clinical stage products comprising AM-102 and AM-123. It has... EARS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT